Tajikistan’s pharmaceutical industry is rapidly evolving, with significant contributions from Sifat Pharma, a key player and client of HLB Tajikistan. The State Program for the Development of the Pharmaceutical Industry (2021-2025) has been instrumental in fostering the growth of 58 domestic enterprises that now produce over 560 types of medicines and medical products. Despite these advancements, the industry still relies heavily on imports, with over 90% of pharmaceutical products sourced from abroad. In 2022, Tajikistan imported $150 million worth of pharmaceutical products, primarily from the United States, India, and China.
Sifat Pharma, as one of the leading companies in the sector, has been actively consolidating and modernizing Tajikistan’s pharmaceutical market. The company has expanded its operations by constructing new factories, increasing its pharmacy network, and focusing on exporting products to Central Asian countries. Through investments in research and development, Sifat Pharma aims to position Tajikistan as a pharmaceutical hub between China and the West.
In the healthcare sector, Tajikistan is making significant strides towards achieving Universal Health Coverage (UHC). Government reforms have prioritized the development of Primary Health Care (PHC), which is crucial for improving the overall health of the population. These reforms include substantial investments in healthcare infrastructure, such as the construction and renovation of healthcare facilities, as well as the training of healthcare workers. The integration of digital technologies into the healthcare system is also playing a critical role in improving access to services, particularly in remote and underserved areas.
The impact of these reforms is evident in the substantial improvements in health outcomes across the country. Maternal and infant mortality rates have significantly decreased over the past two decades, and immunization coverage has expanded, contributing to better public health. However, challenges remain, including high out-of-pocket healthcare expenses and the need for continued investment to sustain these advancements.
Partnering with HLB Tajikistan provides you with access to deep expertise in the pharmaceutical and healthcare sectors. Our team offers strategic consulting, financial advisory, and risk management services to help your business effectively leverage the growth opportunities available in these key industries. With a profound understanding of both local and international markets, HLB Tajikistan is well-positioned to support your business at every stage, ensuring sustainable success. Working with HLB Tajikistan and clients like Sifat Pharma guarantees that you will have the backing you need to achieve your business objectives in a dynamic market environment.
HLB International is a global network of independent advisory and accounting firms, each of which is a separate and independent legal entity, and as such HLB International Limited has no liability for the acts and omissions of any other member. HLB International Limited is an English company limited by guarantee which co-ordinates the international activities of the HLB International network but does not provide, supervise or manage professional services to clients. Accordingly, HLB International Limited has no liability for the acts and omissions of any member of the HLB International network, and vice versa and expressly disclaims all warranties, including but not limited to fitness for particular purposes and warranties of satisfactory quality
Copyright 2024 © All Right Reserved